Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer

Incorporation of HT with concurrent 5FU/MMC had low treatment-related acute and late morbidity with few treatment breaks. However, the expected dosimetric benefit for hematological toxicity was not experienced clinically.